Synthetic host defense peptide inhibits SARS-CoV-2 replication <i>in vitro</i>.

ABSTRACT: Although myriads of potential antiviral agents have been tested against SARS-CoV-2, only a handful have proven to be effective in clinical trials. During the COVID-19 pandemic, many known or novel peptides were evaluated for their ability to inhibit SARS-CoV-2 replication; however, testing of D-enantiomers that resist body and viral proteases has been limited. Here, we characterized the ability of D-3006, a D-enantiomeric synthetic host defense peptide, to inhibit SARS-CoV-2 replication in vitro. A battery of authentic SARS-CoV-2 variants (ancestral, Mu, Delta, and Omicron BA.1) and a comprehensive panel of β-coronavirus spike pseudotyped lentiviruses were used to demonstrate that D-3006 safely (CC₅₀value = 430 µg/mL) blocked spike-mediated entry (EC₅₀ values r

SUBMITTER: Harfoot R 

PROVIDER: S-EPMC12326988 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature